CA2922507C - Single-layer oral dose of neuro-attenuating ketamine - Google Patents

Single-layer oral dose of neuro-attenuating ketamine Download PDF

Info

Publication number
CA2922507C
CA2922507C CA2922507A CA2922507A CA2922507C CA 2922507 C CA2922507 C CA 2922507C CA 2922507 A CA2922507 A CA 2922507A CA 2922507 A CA2922507 A CA 2922507A CA 2922507 C CA2922507 C CA 2922507C
Authority
CA
Canada
Prior art keywords
ketamine
naket
tablet composition
release period
neuro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2922507A
Other languages
English (en)
French (fr)
Other versions
CA2922507A1 (en
Inventor
Alex Nivorozhkin
Nelson Landrau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorsa Therapeutics Inc
Original Assignee
Amorsa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorsa Therapeutics Inc filed Critical Amorsa Therapeutics Inc
Publication of CA2922507A1 publication Critical patent/CA2922507A1/en
Application granted granted Critical
Publication of CA2922507C publication Critical patent/CA2922507C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2922507A 2013-08-26 2014-08-26 Single-layer oral dose of neuro-attenuating ketamine Active CA2922507C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361869884P 2013-08-26 2013-08-26
US61/869,884 2013-08-26
US201462015513P 2014-06-22 2014-06-22
US62/015,513 2014-06-22
PCT/US2014/052786 WO2015031410A1 (en) 2013-08-26 2014-08-26 Single-layer oral dose of neuro-attenuating ketamine

Publications (2)

Publication Number Publication Date
CA2922507A1 CA2922507A1 (en) 2015-03-05
CA2922507C true CA2922507C (en) 2022-07-05

Family

ID=52587281

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2922507A Active CA2922507C (en) 2013-08-26 2014-08-26 Single-layer oral dose of neuro-attenuating ketamine

Country Status (5)

Country Link
US (3) US9913803B2 (enExample)
EP (2) EP3960162A1 (enExample)
JP (2) JP2016531913A (enExample)
CA (1) CA2922507C (enExample)
WO (1) WO2015031410A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
EP3960162A1 (en) 2013-08-26 2022-03-02 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
EP3131533B1 (en) * 2014-04-17 2019-06-05 Develco Pharma Schweiz AG Oral dosage form of ketamine
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
EP3215147B1 (en) 2014-11-04 2024-02-28 ACADIA Pharmaceuticals Inc. Neuro-attenuating norketamine compounds and methods
EP3229788A4 (en) 2014-12-08 2018-06-13 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
WO2018191482A2 (en) * 2017-04-13 2018-10-18 Ovid Therapeutics Inc. Methods of treating developmental encephalopathies
WO2018234568A2 (en) * 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag Hydroxynorketamine for the use in the treatment of depression
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
CN111630026A (zh) * 2017-10-10 2020-09-04 道格拉斯制药有限公司 缓释药物制剂和治疗方法
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
IL275482B1 (en) 2017-12-22 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
EP3813807A1 (en) 2018-06-27 2021-05-05 Clexio Biosciences Ltd. Method of treating major depressive disorder
CN112702995A (zh) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
JP7381597B2 (ja) * 2019-03-25 2023-11-15 ダグラス ファーマシューティカルズ エルティーディー． 持続放出性の医薬製剤
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2021070120A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
US20020160043A1 (en) * 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6855735B2 (en) * 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
RU2004139075A (ru) * 2002-06-10 2005-06-27 Уайт (Us) Новые формиат 0-десметилвенлафаксина
US20080027119A1 (en) * 2002-07-31 2008-01-31 Lippa Arnold S Methods and compositions employing bicifadine for the treatment of acute pain, chronic pain, and symptoms of neuropathic disorders
WO2006053012A2 (en) * 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
WO2008118785A2 (en) * 2007-03-23 2008-10-02 Tikvah Therapeutics Methods for treating depression using immediate-impact treatments and d-cycloserine
CA2685344A1 (en) 2007-04-26 2008-11-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
WO2009131794A1 (en) 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
WO2013003669A2 (en) 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
EP3960162A1 (en) * 2013-08-26 2022-03-02 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
JP6374965B2 (ja) 2013-09-23 2018-08-15 コンヴィオン オサケユキチュアＣｏｎｖｉｏｎ Ｏｙ 高温電池システムのための再循環装置及び方法

Also Published As

Publication number Publication date
US20200261370A1 (en) 2020-08-20
US11554100B2 (en) 2023-01-17
EP3960162A1 (en) 2022-03-02
US20160199304A1 (en) 2016-07-14
US20180153813A1 (en) 2018-06-07
CA2922507A1 (en) 2015-03-05
EP3035918B1 (en) 2021-06-30
JP2020079273A (ja) 2020-05-28
US9913803B2 (en) 2018-03-13
JP2016531913A (ja) 2016-10-13
EP3035918A4 (en) 2017-03-29
WO2015031410A1 (en) 2015-03-05
EP3035918A1 (en) 2016-06-29
US10653629B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
US11554100B2 (en) Single-layer oral dose of neuro-attenuating ketamine
US10300141B2 (en) Tamper resistant dosage form comprising inorganic salt
AU657027B2 (en) Controlled release oxycodone compositions
US20180326067A1 (en) Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
SK284620B6 (sk) Tableta obsahujúca ako účinnú zložku terapeuticky účinné množstvo hydrobromidu galantamínu a spôsob jej prípravy
MX2015002633A (es) Composicion medica oralmente administrada.
EP2606879A1 (en) Multiple unit pellet tablet formulation comprising an opioid
KR20160018702A (ko) 변형 방출 제제
EP3139906B1 (en) A slow-release pharmaceutical formulation
KR102194174B1 (ko) 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손
US20160317662A1 (en) Stable oral pharmaceutical composition
US20180028472A1 (en) Tamper-resistant dosage form comprising a polyethylene glycol graft copolymer
KR101515222B1 (ko) 티아넵틴 나트륨 함유 제어방출성 경구용 단층 제제 및 이의 제조방법
HK1184384A (en) Tamper resistant dosage form comprising inorganic salt
HK1184384B (en) Tamper resistant dosage form comprising inorganic salt

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190822

EEER Examination request

Effective date: 20190822